热门资讯> 正文
Candel暂停了CAN-2409在前列腺癌类型中的开发
2025-11-15 00:47
- Candel Therapeutics (CADL) said it is pausing the development of CAN-2409 specifically for an indication in borderline resectable pancreatic adenocarcinoma, where it is in phase 2 testing.
- The company said that it wants to focus the asset in localized, intermediate/high risk pancreatic cancer and non-small lung cancer. Developed on an adenovirus platform, CAN-2409 is ready for a BLA submission in the former indication and in phase 2 for the latter.
- Candel noted a phase 3 study in NSCLC is slated to begin in Q2 2026.
- The biopharma's Q3 financial results, released on Thursday, missed on the bottom line.
More on Candel Therapeutics
- Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now
- Candel Therapeutics: Potentially The Next Exciting Oncology Story
- Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors
- Candel Therapeutics signs $130M term loan facility with Trinity Capital
- Erasca, Candle, Xencor drop as BofA downgrades on lack of near-term catalysts
推荐文章
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
一周IPO | 赚钱效应持续火热！年内24只上市新股“0”破发；“图模融合第一股”海致科技首日飙涨逾242%
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
美股机会日报 | 降息预期升温！美国1月CPI年率创去年5月来新低；净利、指引双超预期！应用材料盘前涨超10%
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
